872 Combined multi-omics analysis delineates the impact of epigenetic therapies on the immunopeptidome of acute myeloid leukemia

• Hans-Georg Rammensee,
• Elke Schaeffeler,
• Matthias Schwab,
• Juliane S Walz,
• Jens Bauer,
• Marcel Wacker,
• Marissa Dubbelaar,
• Annika Nelde,
• Regina Bohnert,
• Jonas Scheid

Affiliations

Hans-Georg Rammensee

3Cluster of Excellence iFIT (EXC2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, University of Tübingen, Tübingen, Germany

Elke Schaeffeler

2Cluster of Excellence iFIT (EXC2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, University of Tübingen, Tübingen, Germany

Matthias Schwab

8Departments of Clinical Pharmacology, Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany

Juliane S Walz

2Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany

Jens Bauer

3Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany

Marcel Wacker

1University and University Hospital Tübingen, Tübingen, Germany

Marissa Dubbelaar

1Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany

Annika Nelde

2Institute for Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany

Regina Bohnert

4Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany

Jonas Scheid

1Department of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany